The Q4 earnings report for Exact Sciences (NASDAQ: EXAS) was released on Friday, February 13, 2026 at 04:05 PM. Here's what investors need to know about the latest announcement. Exact Sciences missed ...

They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q4 CY2025 results , with sales up 5.2% year on year to $7.93 billion. On the other hand, the company’s full-year revenue guidance of ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Oracle announced the Oracle Life Sciences AI Data Platform, a generative AI-enabled solution designed to empower pharmaceutical, medical device, research, and life sciences organizations to accelerate ...